Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings, Inc. (DNA)
:DNA
RESEARCH TOOLSreports
DNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.26 - $52.80
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.95M
Market Cap
$473.62M
Enterprise Value$252.33M
Total Cash (Recent Filing)-$495.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.19
Next Earnings
May 08, 2025EPS Estimate
-1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.62
Shares Outstanding45,808,500
10 Day Avg. Volume2,587,632
30 Day Avg. Volume1,952,181
Standard Deviation0.23
R-Squared0.08
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.19
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.28
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$9.25Price Target Upside12.26% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Ginkgo Bioworks Holdings News
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementGinkgo has made dramatic reductions on the cost side and expects additional savings by the end of third quarter 2025.
New OfferingsNewer Tools and AI offerings could drive upside for the company.
Bears Say
Revenue GuidanceGinkgo initiated a 2025 revenue guide well below the Street, as the company cited ongoing end market pressures, coupled with some impacts as a result of completing its ~40% workforce reduction.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $5.26 and its highest was $52.80 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $473.62M.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is May 08, 2025 which is in 66 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on Feb 25, 2025. The company reported -$2 earnings per share for the quarter, missing the consensus estimate of -$1.504 by -$0.496.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -1.77.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 45,808,500 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$2 in its last earnings report, missing expectations of -$1.504. Following the earnings report the stock price went down -11.467%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in DNA
---
Ginkgo Bioworks Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.25 (12.26% Upside)
$9.25 (12.26% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 320.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-86.44%
12-Months-Change
Fundamentals
Return on Equity
-60.34%
Trailing 12-Months
Asset Growth
-17.29%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
---
DNA Company Deck
---
DNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While the company showcased strong cash management, cost reduction, and growth in Cell Engineering revenue, it faced challenges with declining full-year revenue in Cell Engineering and Biosecurity, as well as uncertainty in government contracts. The successful launch of new tools and services offerings provided a positive outlook, but these were offset by the revenue declines in key segments.Read More>---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Month Forecast
Average Price Target
$9.25
▲(12.26% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Twist Bioscience
―
Best Analysts Covering DNA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+50.77%
reiterated a sell rating 7 days ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +50.77% per trade.
---